Yi Jiao1,2
Xing Wang1,2Qiong Wang1,2Qishun Geng3Xiaoxue Cao3Mengxiao Zhang2Lu Zhao4
Tingting Deng2
Yuan Xu5*
Cheng Xiao1,2,6*- 1Beijing University of Chinese Medicine, China-Japan Friendship Clinical Medical College, Beijing, China
- 2Institute of Clinical Medicine, China-Japan Friendship Hospital, Beijing, China
- 3Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China
- 4China-Japan Friendship Hospital, Capital Medical University, Beijing, China
- 5Department of TCM Rheumatology, China-Japan Friendship Hospital, Beijing, China
- 6Department of Emergency, China-Japan Friendship Hospital, Beijing, China
The immune system plays a crucial role in regulating osteoclast formation and function and has significance for the occurrence and development of immune-mediated bone diseases. Kidney-tonifying Chinese herbs, based on the theory of traditional Chinese medicine (TCM) to unify the kidney and strengthen the bone, have been widely used in the prevention and treatment of bone diseases. The common botanical drugs are tonifying kidney-yang and nourishing kidney-yin herbs, which are divided into two parts: one is the compound prescription of TCM, and the other is the single preparation of TCM and its active ingredients. These botanical drugs regulate osteoclastogenesis directly and indirectly by immune cells, however, we have limited information on the differences between the two botanical drugs in osteoimmunology. In this review, the mechanism by which kidney-tonifying Chinese herbs inhibiting osteoclastogenesis was investigated, emphasizing the immune response. The differences in the mechanism of action between tonifying kidney-yang herbs and nourishing kidney-yin herbs were analysed, and the therapeutic value for immune-mediated bone diseases was evaluated.
1 Introduction
Osteoclasts (OCs) originate from the monocyte/macrophage lineage and form large multinucleated cells through cell-cell fusion. Kodama and Kaito, (2020) Osteoclastogenesis is a complex process that requires multiple cytokines, such as receptor activator of nuclear factor (NF)-κB ligand (RANKL), macrophage colony stimulating factor (M-CSF), interleukin (IL), and tumor necrosis factor (TNF), to activate OC differentiation and promote bone resorption. Zhou et al. (2022) M-CSF and RANKL exposure induced the differentiation of OC precursor cells, which were encouraged to proliferate and survive by M-CSF and to differentiate by RANKL; Teitelbaum, (2000) RANKL induces the receptor RANK on the OC surface, which directly recruits tumour necrosis factor receptor-associated factor (TRAF) 6 and activates downstream related signalling pathways, while osteoprotegerin (OPG) competes with RANKL to bind RANK, which induces the activation of various signal transduction pathways, such as the nuclear factor-κB (NF-κB), protein kinase B, PKB (AKT) and mitogen-activated protein kinase (MAPK). Park et al. (2017); Boyle et al. (2003) Nuclear factor of activated T cells (NFAT) c1 and c-Fos act as important transcription factors for OCs, Takayanagi et al. (2002) promoting the expression of genes encoding proteins, such as tartrate-resistant acid phosphatase (TRAP), cathepsin K (CTSK), matrix metallopeptidase (MMP), dendritic cell-specific transmembrane protein (DC-STAMP) and OC stimulatory transmembrane protein (OC-STAMP), to fuse and mature precursor cells. Boyce, (2013) Mature OCs fused by multinucleated cells have folded edges, adhere to the bone matrix, and release protons, chloride and related cathepsins, such as H+, MMP, TRAP, and CTSK, which can effectively degrade collagens and other bone proteins, leading to the dissolution of mineralized matrix; Boyle et al. (2003); Søe et al. (2021) Bone resorption caused by mature OCs on the surface of bone marrow maintains bone homeostasis together with osteoblasts (OBs) that play a role in bone formation. Excessive osteoclastogenesis leads to bone diseases, such as osteoporosis (OP), rheumatoid arthritis (RA), osteosarcoma, and osteopetrosis, (Yao et al., 2021) and disorders of the immune system mediate the process of disease progression; Wu et al. (2021); Andreev et al. (2022); (Figure 1).
FIGURE 1. Schematic diagram of the interaction between immune cells and osteoclasts (OCs). Various immune cells and secreted cytokines act on OCs and osteoblasts (OBs) to maintain bone homeostasis on the bone surface. Th-cell subsets (Th1, Th2, Th17, Treg) play an important role in modulating the differentiation and maturation of OCs. Th1 cells secrete IFN-γ, IL-2, TNF-α and RANKL and Th2 cells secrete IL-4, IL-10, and IL-13 to regulate osteoclastogenesis. Th17 cells secrete IL-17, RANKL and TNF-α to enhance OC differentiation and bone resorption. CD4+ Tregs promote the bone formation and secrete CTLA-4, TGF-β, IL-10 and IL-4 to promote apoptosis and inhibit bone resorption. CD8+ Tregs secrete IFN-γ to inhibit the formation of the actin ring and OC activity. However, B cells secrete OPG and RANKL to regulate bone health. The two subtypes (M1 and M2) of macrophages (Mφs) differentiate into OC and secrete cytokines to regulate osteoclastogenesis. Monocytes (Mo), dendritic cells (DC) and neutrophils and cytokines are associated with OC formation and function. Pre-OCs are derived from monocytes/macrophages and differentiate into mature OCs under stimulation with M-CSF and RANKL. RANKL induces the receptor RANK on the OC surface, which recruits TRAF6 to activate downstream pathways and transcription factors. OC precursors fuse into multinucleated cells and then secrete H+, TRAP, MMP, and CTSK to absorb bone on the bone surface. Pre-OBs are derived from mesenchymal precursors and differentiate into mature OBs, which support bone formation on the bone surface.
Osteoimmunology helps to formulate treatment strategies for various immune-mediated bone diseases involving the bone and the immune systems, and it also highlights the increasingly important role of the immune system in bone health. The topic covers both the indirect relationships between transcription factors, cytokines, and their receptors as well as the direct relationships between the essential cells of the two systems. Okamoto et al. (2017) Through molecular mechanisms, various types of cells in the immune system, including T lymphocytes, B lymphocytes, and macrophages (Mφs), regulate OCs, OBs, chondrocytes, mesenchymal stem cells (MSCs) and other bone cells. Deng et al. (2021) OCs are innate immune cells in bone and have immunological functions in addition to bone absorption; Wu et al. (2008) Its pathological changes are characterized by immunological alterations; Madel et al. (2019) Many studies have proven that T cells and derived cytokines can regulate OCs; Kong et al. (1999); Takayanagi et al. (2000); Sato et al. (2006); Kelchtermans et al. (2009); Levescot et al. (2021) Immune-mediated bone diseases include RA, postmenopausal osteoporosis (PMOP), psoriasis arthritis and ankylosing spondylitis (AS). The infiltration of immune cells and cytokines secreted by immune cells are important mechanisms causing joint deformity and dysfunction. Tang et al. (2020) T-cell-mediated inflammation is an important factor affecting bone mass in PMOP (Wu et al. 2021), and studies have shown that ovariectomy (OVX)-mice lacking T cells have reduced bone loss. Roggia et al. (2001) The regulatory effect of inflammatory factors on MSCs, OBs, and OCs mainly affects the disease progression of PMOP. Ilesanmi-Oyelere et al. (2019); Liao et al. (2020) In the pathogenesis of RA, the inflammatory response disrupts bone homeostasis, leading to bone loss and fractures. Initially, the body develops autoreactive antibodies due to certain factors, followed by autoantibodies, epitopes and inflammatory markers gradually increasing, leading to bone erosion. Finally, immune cells are recruited into the joints, and the inflammatory response is repeatedly cycled and gradually amplified. Andreev et al. (2022) Thus, immune cells and their secreted products in immune-mediated bone diseases activate a variety of pathways, which together comprehensively enhance the differentiation of OCs.
Traditional Chinese medicine (TCM) holds the theory that “kidney governs bone” (Ju et al. 2014), thus, bone diseases are mostly treated from the kidney. Kidney-tonifying Chinese herbs is based on the theory of TCM and has the effect of tonifying the kidney and strengthening the bone, and the common botanical drugs have been tonifying kidney-yang and nourishing kidney-yin herbs according to the medicinal properties and taste since ancient times. Wang et al. (2022b); Zhu et al. (2022) Kidney yang tonifying refers to promoting physiological functions and acting as a facilitator, while kidney yin nourishing refers to providing the subtle material basis for bone conservation, acting as a nourisher. Kidney yang-tonifying herbal medicines include Epimedium brevicornu Maxim. (Epimedii Folium), Morinda officinalis F.C. How (Morindae Officinalis Radix), Curculigo orchioides Gaertn. (Curculiginis Rhizoma), Eucommia ulmoides Oliv. (Eucommiae Cortex), Cullen corylifolium (L.). Medik. (Psoraleae Fructus), Drynaria roosii Nakaike (Drynariae Rhizome), Cnidium monnieri (L.) Cusson (Cnidii Fructus), while kidney yin-nourishing herbal medicines include Polygonatum sibiricum Redouté (Polygonati Rhizome), Eclipta prostrata (L.) L. (Ecliptae Herba), Ligustrum lucidum W.T.Aiton (Ligustri Lucidi Fructus), Rehmannia glutinosa (Gaertn.) DC. (Rehmanniae Radix Praeparata). Zhou and Tang, (2016) Chinese formulae (Han and Kim 2021), botanical drugs (Liu et al. 2017), and natural products (Wang et al. 2018b) used to tonify the kidney have been proven to regulate OCs and OBs and improve bone structure and function to prevent and treat immune-mediated bone diseases with high clinical effectiveness and safety. Kidney-tonifying Chinese herbs have a direct regulatory effect on OCs, but in recent years, based on the close relationship between OCs and the immune system, research into kidney-tonifying herbs controlling OCs via the immune system has gained attention. Xia et al. (2021); Zhang et al. (2018); Zhao et al. (2018c) The compound prescription of TCM is the basic form of clinical application in the treatment of immune-mediated bone diseases, and its mechanism of inhibiting osteoclastogenesis through immune cells is relatively clear. But we have limited information on the discussion of the compound prescription of TCM and the differences between the tonifying kidney-yang herbs and nourishing kidney-yin herbs in osteoimmunology. Hence, the review selected the compound prescription, the single preparation and its active ingredients to comprehensively discuss the regulatory mechanism of kidney-tonifying Chinese herbs on OC formation and function from the perspective of immunity, to compare the differences between tonifying kidney-yang and nourishing kidney-yin herbs, and to evaluate the therapeutic value of immune-mediated bone diseases.
2 Effects of immune cells on OC formation and function
Since the advent of the field of osteoimmunology, a growing number of studies have focused on the control of OC formation and function through the immune system. OCs are not only phagocytes for bone resorption but are also innate immune cells involved in the control of the immune response. Madel et al. (2019) It was initially believed that the costimulatory signals mediated by immunoreceptor tyrosine-based activation motifs (ITAMs) activated by immune cells were essential for osteoclastogenesis, except for RANKL and M-CSF. Koga et al. (2004) The proliferation, differentiation, fusion, bone adhesion and bone degradation of OCs require the participation of immune cells and secreted cytokines. Del Fattore and Teti, (2012); Madel et al. (2019).
T cells are the core of osteoimmunology. The effect of T cells on osteoclastogenesis depends on the balance of positive and negative factors expressed by T cells. Sato et al. (2006) Only IL-17- expressing Th17 cells have been shown to increase OC formation and bone destruction by promoting the inflammatory response and increasing RANKL expression in OC precursors. In contrast, other T-cell-derived cytokines have a negative effect on osteoclastogenesis. IL-23-stimulated Th17 cells mainly promote osteoclastogenesis by producing IL-17. Sato et al. (2006) IL-17 facilitates local inflammation by recruiting and activating immune cells, resulting in an abundance of inflammatory cytokines, such as TNF-α. Weaver et al. (2006) Inflammatory cytokines enhance RANKL expression, and Th17 cells support osteoclastogenesis through RANKL and CD40L. Gohda et al. (2005) Regulatory T cells (Tregs) secrete M-CSF, transforming growth factor (TGF)-β, IFN-γ, IL-4, IL-10, and IL-5 to inhibit osteoclastogenesis and bone resorption. Kim et al. (2007); Luo et al. (2011); Kelchtermans et al. (2009) A study found that Tregs suppressed the OC differentiation and decreased the areas that were resorbed in cocultures system of Tregs and mouse bone marrow macrophages (BMMS). (Xu et al. 2016b). On the other hand, through CTLA-4 and CD80/86, OC differentiation is inhibited by means of intercellular contact. Axmann et al. (2008) Another study found that CD8+ Tregs regulate actin ring formation to inhibit the maturation and activity of OCs via IFN-γ. Shashkova et al. (2016) These three mechanisms jointly lead to osteoprotective effects mediated by Tregs. Further studies revealed that gut microbiota and AhR promote the differentiation and function of Tregs to enhance immune tolerance, and that Tregs acted on OCs in both a targeted T cell and antigen-presenting cell (APC) manner. Li et al. (2021)Th1 and Th2 are pioneers in regulating bone health and have bone protection effects in bone immunity. Most cytokines produced by Th1 cells inhibit osteoclastogenesis, including IFN-γ, IL-2, TNF-α, and M-CSF. IFN-γ has both direct anti-osteoclastogenic and indirect pro-osteoclastogenic effects by stimulating T-cell activation and RANKL and TNF-α expression. Gao et al. (2007) TNF-α also has positive and negative effects on the formation of OCs, mainly differentiating M2 macrophages induced by M-CSF into M1 macrophages with the potential to enhance OC formation, but it also inhibits NFATc1 activation and limits RANKL-induced osteoclastogenesis. Zhao et al. (2015) Th2 cells are created by activating CD4+ T cells in the presence of IL-4, which causes the production of cytokines. The cytokines IL-4 and IL-13 produced by Th2 cells are associated with the inhibition of osteoclastogenesis and OC differentiation, significantly lowering the RANKL/OPG ratio (Palmqvist et al. 2006), and the cytokine IL-10 is involved in immune inflammatory events in OCs. Gonzalez et al. (2022) New pathways and molecular mechanisms between Th17 cells, Tregs and OCs need to be explored more comprehensively, which is very important for pathological mechanisms and drug research of clinical osteopathy (Figure 1).
Although T cells play a major role in controlling the differentiation of OCs, B cells can also impact problems with OCs, but the regulatory effect of B cells on OCs is still controversial. B cells produce OPG and RANKL to maintain bone homeostasis and support OC differentiation and maturation by regulating the OPG/RANKL/RANK pathway. Grčević et al. (2021); Meednu et al. (2016) On the other hand, B cells act as OC progenitor cells, which may have the potential to produce OCs. Manabe et al. (2001) B cells inhibit OC formation when activated by Th1 cytokines. Choi and Kim, (2003) In turn, OCs regulate the development of B cells by controlling the bone microenvironment and OBs. Mansour et al. (2011) (Figure 1).
The fusion and multinucleation of OCs are attributed to membrane fusion and reprogramming of Mφs. Yao et al. (2021) Mφs, as precursors of OCs, have the potential to differentiate into mature OCs. The two subtypes (M1, M2) differentiate into OC under the conditions of RANKL and M-CSF or RANKL, respectively. Saxena et al. (2021) Oestrogen inhibits M2 polarization mediated by RANKL differentiation into OCs. Dou et al. (2018) This differentiation process is regulated by many factors. Peroxisome proliferator-activated receptor (PPAR)γ, oestrogen-related receptor (ERR)α, PPARγ coactivator (PGC)1β and others have been newly discovered to be involved in OC differentiation in recent years in addition to energy metabolism. Yao et al. (2021) The M1phenotype is an inflammatory that is activated by cytokines, and its related cytokines can promote OC formation and bone resorption, while the M2 phenotype is a repair in which related cytokines, such as IL-4 and IL-10, can inhibit OC function and promote osteogenesis. Xu et al. (2022); Yang and Wan (2019) (Figure 1).
It has been reported that other innate immune cells also have the potential to differentiate into OCs or affect OC formation and function by producing cytokines. Saxena et al. (2021) As the precursor of OCs, monocytes (Mo) are recruited from the blood circulation to the bone surface and differentiate into OCs. Sprangers et al. (2016) Dendritic cells (DCs) differentiate into OCs in an inflammatory state, and DCs act as APCs to activate T cells to promote bone remodelling. Rivollier et al. (2004) Neutrophils, as a type of multinucleated phagocyte, express RANKL to promote bone resorption, while RANK expression depends on TNF-α and IL-4. Poubelle et al. (2007) Infiltration of natural killer (NK) cells in the joint will aggravate the pathological process of RA. Wu et al. (2022a) NK cells mediate the production of RANKL and M-CSF to promote the production of OCs, and induce Mos to differentiate into OCs. Söderström et al. (2010) NK cells inhibit bone destruction through direct contact with OCs or secretion of IL-15. Feng et al. (2015) It shows that NK cells have dual effects on osteoclastogenesis. It can be seen from the above that innate and adaptive immune cells play a key role in the osteoclastogenesis process. Targeting immune cells or related cytokines could inhibit OC formation and function and be used to treat immune-mediated bone diseases. In recent years, the role of N6-methyladenosine (m6A) modification has also been recognized as one of important factors in regulating Mφ and DC activation and function, and T cell homeostasis (Fan et al. 2020), providing a new perspective on osteoimmunology (Figure 1).
3 Immunoregulation mechanisms by which tonifying kidney-yang herbs inhibit osteoclastogenesis
3.1 The compound prescription of Traditional Chinese medicine
3.1.1 Yi Shen Juan Bi pill
The pill contains botanical drugs including Drynariae Rhizoma, Cistanches Herba and Epimedii Folium, which are used to tonify kidney-yang and strengthen bones. According to the research, Yi Shen Juan Bi pill could affect the activation and differentiation of OCs caused by RA by regulating the phenotypic balance of T cells, upregulating the percentage of Tregs, such as IL-10 and TGF-β1 levels, and downregulating the percentage of Th1 and Th17 cells, such as IFN-γ and IL-17A levels. Wang, (2017); Zhao et al. (2018b) Both in vivo and in vitro experiments showed that Yi Shen Juan Bi pill directly inhibited the bone resorption function of OCs by inhibiting the JAK2/STAT3 pathway and upregulating the ephrin B2 pathway to downregulate the expression of OC transcription factors, such as c-Fos, c-Jun, NFATc1, RANK, HMGB1 and RAGE. Guo et al. (2018); Cao, (2021); Xia et al. (2021) Further coculture of Tregs and OCs showed that it could also inhibit the JAK2/STAT3 pathway in Tregs to enhance the immunosuppressive effect of Tregs and indirectly inhibit bone resorption function. Xia et al. (2021) Early studies have shown that it can target the inflammatory and immune regulatory responses of Mφs to reduce the production of TNF-α, IL-1 and NO derived from Mφs in the abdominal cavity. Perera et al. (2011).
3.1.2 Bu Shen Tong Luo formula
Drynariae Rhizoma and Epimedii Folium are the most abundant in the formula. The Bu Shen Tong Luo formula could regulate CD3, CD4, and CD8 T cells to improve the joint score of CIA-rats (Su et al. 2010), and it could inhibit the differentiation and maturation of OCs and bone absorption, promote bone reconstruction, alleviate systemic inflammatory response and joint swelling to treat RA and PMOP through the Chemerin, NF-κB, OPG/RANK/RANKL pathways. Han, (2021); Liu et al. (2021a) Its osteoprotective effects may be related to the stimulation of HIF-1α/VEGF angiogenesis. Yuan et al. (2018).
3.1.3 Jia Wei Yang He decoction, Deerhorn Glue pill, Ai Ke Qing granule
The combination of RANKL and M-CSF was used to induce RAW264.7 cells to differentiate into OCs. Cervi Cornu and Epimedii Folium are the botanical drugs to tonify kidney-yang mainly in the three prescriptions. Yang et al. also found that Jia Wei Yang He decoction inhibited OC activity and reduced TRAP activity secreted by OCs through the NF-κB pathway. Yang et al. (2022) suggested that Deerhorn Glue pills could improve bone structure, increase bone strength, inhibit bone absorption and promote OC apoptosis through PI3K/AKT. Yu et al. (2018); Yu et al. (2020) It was found that Ai Ke Qing granules could inhibit OC to treat PMOP, which inhibited the binding of RANK and TRAF6 and affected the activation of downstream NF-κB, p38 and JNK pathways to inhibit functional genes, OC surface receptor genes, OC precursor cell fusion genes, bone resorption functional proteins and transcription factors. Liu (2021) There are many tonifying kidney yang formulae, but they focus on the role of OC differentiation and absorption, and research on immune cells and related cytokines is lacking.
3.1.4 Yi Shen Bu Gu liquid and Bu Shen Qu Han Zhi Wang decoction
In vivo experiments showed that the Chinese herbal prescription for tonifying kidney yang could regulate the inflammatory response, oxidative stress response and downstream pathway through the OPG/RANK/RANKL pathway and play a role in inhibiting OC differentiation. Psoraleae Fructus and Drynariae Rhizoma are the botanical drugs to tonify kidney-yang mainly in the two prescriptions. Yi Shen Bu Gu liquid upregulated IL-33 and downregulated IL-1, IL-7, and TNF-α levels to reduce the inflammatory reaction and increased serum superoxide dismutase (SOD) and catalase (CAT) levels to reduce the oxidation reaction to inhibit OC formation. Li (2021) Bu Shen Qu Han Zhi Wang decoction suppressed OC activity through OPG/RANK/RANKL, reducing the expression of MMP-13, TNF-α, IL-1, IL-2, IL-17, and RANKL to cure RA Li et al. (2017); Ma, (2021); Wu et al.,(2018); Yan, (2012); (Figure 2); (Table 1). These traditional Chinese medicine formulae of tonifying kidney-yang herbs for osteoclastogenesis are preliminarily studied from the cytokines, but the potential immunoregulation mechanisms need to be further explored using immune cells.
FIGURE 2. Schematic diagram of immunoregulation mechanisms of kidney-tonifying herbs on inhibiting osteoclastogenesis. Kidney-tonifying herbs inhibit Th1, Th2, Th17, BMSC and related cytokines and activate Th1, Treg, BMSC and related cytokines to suppress the RANKL/RANK, NF-κB, MAPK, AKT, JAK/STAT signalling pathways, transcription factors NFATc1, c-Fos, and OC genes, which play a role in OC formation and function. Blue represents tonifying kidney-yang botanical drugs, while green represents nourishing kidney-yin botanical drugs. Arrows (↓) indicate positive impact, while inverted Ts (⊥) indicate negative impact.
TABLE 1. Immunoregulation mechanisms by which tonifying kidney-yang of TCM compound prescription inhibit osteoclastogenesis.
3.2 Single preparation of Traditional Chinese medicine and its active ingredients
3.2.1 Drynariae Rhizoma and its active ingredients
Drynariae Rhizoma, the dried rhizome of Drynaria fortunei J. Sm., is a type of medicine for tonifying kidney yang, and its active substance is mainly naringin, which is widely used in the treatment of OP and fracture. Zhang et al. (2017b) A previous study showed that Drynariae Rhizoma possessed immunoregulatory activity, which stimulated the proliferation of the human osteoprecursor cells, promoted alkaline phosphatase activity and protein secretion, and stimulated cellular and humoral immunity. Jeong et al. (2005) Current studies found that it inhibited the differentiation of Mφs into OC by downregulating the expression of RANKL, NFATc1, Fra-1, Fra-2, c-fos, and CTSK and upregulating the expression of OPG, Wnt10b, and β-catenin. Xu et al. (2020); Cheng et al. (2019); Qiu et al. (2016b); Zhang et al. (2019b) Rhizoma Drynariae Flavonoids positively regulated the immune function of immunocompromised mice by increasing the number of leukocytes in peripheral blood, spleen index, thymus index, the expression of inflammatory factors and the ratio of CD4+ T/CD8+ T cell (Zhao et al. 2016), while it regulated the OC function of the OVX rats by regulating the OPG/RANKL/RANK pathway. Song et al. (2016a) Its active substance naringin could inhibit NF-κB activation, IκB-α degradation and ERK phosphorylation and downregulate the expression of related genes induced by RANKL to inhibit the differentiation of Mφs into OCs. Ang et al. (2011); Li et al. (2015) Other studies have found that naringin promotes OCs apoptosis by regulating the mitochondrial apoptosis pathway, downregulating BCL-2, and upregulating Bax, caspase-3 and cytochrome C. Li et al. (2014).
3.2.2 Epimedii Folium and its active ingredient
Icariin is the main active substances in Epimedii Folium, which inhibits the expression of various genes involved in OC formation and bone resorption through the immune response. Icariin reduced Th17 cells by inhibiting STAT3 activation and suppressed IL-17 production, which contributed to the inhibition of cartilage and bone degradation in RA. Chi et al. (2014) In vitro experiments showed that icariin inhibited reactive oxygen species and the NF-κB, MAPK and AKT pathways in OCs and promoted negative regulators to inhibit osteoclastogenesis genes and inflammatory factors. Ji et al. (2022); Xu et al. (2019); Hsieh et al. (2011); Li et al. (2022) The results of clinical trials showed that icariin plays an anti-inflammatory role by promoting the apoptosis of CD4+ lymphocytes in patients with ankylosing spondylitis. Wang et al. (2017) In addition, icariin decreased inflammatory factor expression to inhibit OC formation in titanium particle-charged calvariae and can be used to treat aseptic loosening after arthroplasty. Shao et al. (2015) Other studies have shown that icariin promoted osteogenic differentiation and inhibited OC differentiation by improving the osteogenic activity of MC3T3-E1 cells, inhibiting the OC activity of RAW264.7 cells, reducing the adipogenic differentiation level of bone marrow-derived mesenchymal stem cells (BMSCs), and blocking the osteoclastogenesis induced by MCF7 and MDA-MB-231 breast cancer cells. Kim et al. (2018); Zhang et al. (2017a).
3.2.3 Psoraleae fructus and its active ingredients
The active substances of Psoraleae Fructus are neobavaisoflavone and psoralen. Psoraleae Fructus, as a Chinese botanical drug for treating RA, reduced the percentages of CD4+ IL-17A+, CD4+ TNF-α+, and CD4+ IFN-γ+ cells in the spleen and the expression of inflammatory factors by increasing myeloid-derived suppressor cells (MDSCs) (Pai et al. 2021), four of which can inhibit RANKL-induced osteoclastogenesis. Lee et al. (2021) Psoralen promoted the balanced development of CD4+ CD25+ Treg/Th17 to CD4+ CD25+ T cells by promoting Foxp3, TGF-β and IL-10 levels and inhibiting RORγt, IL-17 and TNF-α levels in CD4+ T cells to downregulate OC differentiation-related genes through AP-1 pathways (Li et al. 2018; Chai et al. 2018), and reduced the expression of IL-8 and PTHrP to inhibit the interaction between OCs, OBs and cancer cells and to reduce the burden of bone metastasis caused by breast cancer. Wu et al. (2013) Neobavaisoflavone, another potential bioactive compound, was proven to inhibit osteoclastogenesis and OC function in vitro and in vivo. Neobavaisoflavone was found to block NFATc1 nuclear translocation and inhibit the activation of the NF-κB, MAPK and AKT pathways and the expression of MMP9, CTSK, CTR and TRAP by disrupting the recruitment of TRAF6 and c-Src molecules by the RANK receptor at the cell membrane. Chenet al. (2020a).
3.2.4 Curculiginis Rhizoma and its active ingredient
Curculigoside is an important active substance of Curculiginis Rhizoma, which is used to treat OP, arthritis and osteolysis. In vivo studies have found that curculigoside reduced the spleen and thymus indices and the expression of inflammatory factors in the serum of CIA rats, such as TNF-α, IL-1β, IL-6, IL-10, IL-12 and IL-17A, while inhibiting the expression of inflammatory factors in Ti-induced osteolysis model mice and restoring the RANKL/OPG ratio. The results showed that curculigoside inhibited osteoclastogenesis and alleviated oxidative stress by activating Nrf2 and inhibiting the NF-κB pathway, alleviated the inflammatory response in MH7A cells through the JAK/STAT/NF-κB pathway, alleviated the expression of inflammatory factors and OC genes in BMSCs, and weakened mitochondrial damage in MC3T3-E1 cells. Liu et al. (2021a); Zhu et al. (2021); Tan et al. (2019) In addition, studies have shown that curculigoside can reverse the immunosuppression caused by cyclophosphamide and proinflammatory cytokines in serum and has anticancer potential against cancer cell lines, such as HepG2, HeLa and MCF-7 (Murali and Kuttan 2015; Hejazi et al. 2018), which may have certain therapeutic value for bone metastasis after the development of a tumour.
3.2.5 Morindae officinalis radix and its active ingredients
Morinda officinalis polysaccharide, bajijiasu and rubiadin-1-mrthyl ether are the active components of Morindae Officinalis Radix, which is commonly used to treat RA and OP and has obvious therapeutic effects on senile, postmenopausal, and glucocorticoid osteoporosis. Morinda officinalis could improve atrophy of the spleen and thymus by increasing the number of CD4+ cells and reducing the number of CD8+ cells in the peripheral blood of immunosuppressive mice induced by cyclophosphamide. Wei et al. (2019) Morinda officinalis polysaccharide could enhance the immune and anti-inflammatory function of psoriasis patients, enhance the growth capacity of Tregs, and weaken immune and proinflammatory functions. Yin, (2017) It protected bone loss and biomechanical dysfunction in OVX-rats and had antiosteoporosis activity through OPG/RANK/RANKL (Zhang et al. 2020; Peng and Zhong 2020), while inhibiting OC differentiation through the exosomes of mesenchymal stem cells, which was closely related to the expression of PTGS2 and miR-101-3p. Wu et al. (2022c) Bajijiasu and Rubiadin-1-mrthyl ether inhibited the expression of OC-specific genes induced by RANKL through the NF-κB pathway to inhibit OC generation and function and treat osteolytic bone diseases. Hong et al. (2017); He et al. (2018).
3.2.6 Other single botanical drugs and their active ingredients
There are other tonifying kidney-yang botanical drugs with the functions of tonifying the kidney, strengthening the yang and strengthening the muscles and bones, which are often used to treat immune-mediated bone diseases, but the mechanism of action on immunity needs to be further studied. Eucommiae Cortex can be used to treat OP and RA, and its active components include polysaccharides, iridoid glycosides, and flavonoids. It was found that ethanol extracts from Eucommiae Cortex alleviated the inflammatory response through the OPG/RANK/RANKL and NF-κB pathways to delay the destruction of intraarticular cartilage and bone. Zhang et al. (2021); Wang et al. (2022a); Zhang et al. (2014) The ethanol extracts and polysaccharides from Eucommiae Cortex increased the coefficient of the thymus and spleen and improved the clearance ability and phagocytosis ability of peritoneal Mφs in mice. Qiu et al. (2008); Ye et al. (2015) Osthole may restore BMSC-mediated T-cell migration and apoptosis by stimulating the expression of Fas/FasL, enhancing the immune activity of BMSCs in healthy or inflammatory microenvironments to treat OP (Yu et al. 2021), and downregulating c-Scr, β3-integrin and OC genes to inhibit OC formation and bone resorption. Ma et al. (2019); Zhao et al. (2018a); (Figure 2); (Table 2).
TABLE 2. Immunoregulation mechanisms by which tonifying kidney-yang of single preparations and their active ingredients inhibit osteoclastogenesis.
4 Immunoregulation mechanisms by which nourishing kidney-yin herbs inhibit osteoclastogenesis
4.1 The compound prescription of Traditional Chinese medicine
4.1.1 Bu Shen Ning Xin decoction
Rehmanniae Radix Praeparata is the main nourish kidney-yin component of the decoction. The Bu Shen Ning Xin decoction can treat PMOP by regulating osteoclastogenesis. A previous study suggested that Bu Shen Ning Xin decoction abrogated RANKL-mediated NFATc1 and NF-κB pathways through selective oestrogen receptor (ER)α. Wang et al. (2015) Later, CD4+ T cells were cocultured with BMMs to investigate the immune modulatory effects of Bu Shen Ning Xin decoction on CD4+ T cells and osteoclastogenesis, and the findings suggest that Bu Shen Ning Xin decoction has an immune-regulating effect on the bone phenotype of OVX mice by changing the immune environment, increasing CTLA-4+ Tregs and the apoptosis rate of CD4+ T cells and regulating the RANKL/OPG imbalance in CD4+ T cells. Qiu et al. (2016a); Zhang et al. (2018).
4.1.2 Zuo Gui Wan
Rehmanniae Radix Praeparata is the main nourish kidney-yin component of the Zuo Gui Wan, which prevented bone loss by downregulating IL-6 and RORγt, upregulated Foxp3 in OVX mice and skewed the Th17/Treg paradigm to Treg (Lai et al. 2015), which may be related to the OPG/RANKL pathway mediated by β2-adrenergic receptor (β2AR). Liu et al. (2018) Further experimental results show that Zuo Gui Wan inhibited bone resorption by inhibiting OC proliferation and differentiation and promoting OC apoptosis. Zhang, (2019).
4.1.3 Yukmijihwang-Tang
Rehmanniae Radix Praeparata is the main nourish kidney-yin component of the Yukmijihwang-Tang, which inhibited RANKL-induced OC differentiation, resorption and fusion and OC differentiation in the coculture system of bone marrow cells (BMCs) and OBs and BMMs and downregulated OC-related genes, which may be related to the inhibition of the p38, JNK, ERK, and NF-κB signalling pathways. Han and Kim, (2021); Shim et al. (2011) Moreover, the study found that it upregulated the expression of the immune-related gene IRF1 in the JAK/STAT pathway in PMOP patients with kidney yin deficiency. Chen et al. (2017) However, its mechanism has not been explored with regard to immune cells.
4.1.4 Erzhi formula
Ligustri Lucidi Fructus and Ecliptae Herba make up Erzhi formula, which is used to treat kidney yin deficiency. Erzhi formula improved PMOP by controlling the OPG/RANK/RANKL signalling axis, and suppressing the expression of OC differentiation genes, such as CTSK, TRAP and NFATc1, which may be related to inhibiting cell autophagy, controlling oestradiol, and nourishing the uterus. Qin et al. (2021); Tian et al. (2020) Meanwhile, Erzhi formula had a protective effect on immunocompromised mice and could improve the activity level of T lymphocyte factor. Yao et al. (2014) At present, there is only network pharmacological analysis of the Erzhi formula in RA, and basic research to prove the relevant mechanism is lacking. (Figure 2); (Table 3).
TABLE 3. Immunoregulation mechanisms by which nourishing kidney-yin of TCM compound prescription inhibit osteoclastogenesis.
4.2 Single preparation of Traditional Chinese medicine and its active ingredients
4.2.1 Ecliptae Herba and its active ingredient
Ligustri Lucidi Fructus and Ecliptae Herba are two single botanical drugs of Erzhi formula. Wedelolactone is the active ingredient of Ecliptae Herba. Wedelolactone inhibited the production of Sema3A, Sema4D and Sema7A and the number of Sema4d-plexinB1 and plexinA1-DAP12 complexes in BMSCs, and inhibited RANKL-induced F-actin ring formation and bone resorption pits to inhibit osteoclastogenesis and bone resorption. Deng et al. (2018); Liu et al. (2016a); Liu et al. (2016b) Wedelolactone inhibited breast cancer-mediated osteoclastogenesis and OC activity in CD14+ monocytes through the AKT-mTOR pathway to treat bone metastasis after breast cancer. Hsieh et al. (2015).
4.2.2 Ligustri Lucidi Fructus and its active ingredient
Studies have shown that Ligustri Lucidi Fructus could upregulate the gene expression of the T-cell receptor signalling pathway. Zheng et al. (2018) The extract of Fructose Ligustri Lucidi upregulated the levels of IL-2 and IFN-γ produced by Th1 lymphocytes, and downregulated the level of IL-10 produced by Th2 lymphocytes (Wang et al. 2012), while it inhibited OC differentiation and bone resorption by inhibiting RANKL-induced OC formation and TRAP activity and reduced OC differentiation genes in RAW264.7 cells. Xu et al. (2016a).
4.2.3 Polygonati Rhizome and its active ingredient
Polygonatum sibiricum polysaccharide are some of the main components of Polygonati Rhizome. Polygonatum polysaccharide promoted the development of immune organs, lymphocyte proliferation, natural killer cell (NK) activity and phagocytosis of Mφs, increased the ratio of CD4+/CD8+, and mediated the release of cytokines at the cellular and transcriptional levels to reverse immunosuppression (Chen et al. 2020b; Zhang et al. 2019a), and it inhibited OC differentiation in BMMs through the Hippo signalling pathway based on miR-1224 and maintained bone mass in LPS-induced skull osteolysis-mice. Du et al. (2016); Li et al. (2019).
4.2.4 Rehmanniae Radix Praeparata and its active ingredient
Two polysaccharides in Rehmanniae Radix Praeparata promoted phagocytosis of RAW264.7 cells and increased lysozyme activity in a dose-dependent manner. Zhou et al. (2021) At the same time, they have immune activity by promoting the activation of human dendritic cells and T cells and inducing the expression of costimulatory molecules and the production of proinflammatory cytokines. Wang et al. (2018a) Catalpol extracted from Rehmanniae Radix Praeparata upregulated the activity of phosphatase and tensin homologue (PTEN) by reducing ubiquitination and degradation, subsequently suppressing the NF-κB and AKT pathways induced by RANKL but had no effect on the MAPK pathway, leading to an inhibition of OC activity to avoid bone loss. Meng et al. (2020) Its immune mechanism may be related to the fact that catapol could inhibit the traditional differentiation and inflammatory factors of Th17 and inhibit the transdifferentiation of Treg-to-Th17 cells associated with STAT3 by upregulating let-7g-5p. Di et al. (2022) Acteoside is the active substance of Rehmanniae Radix Praeparata, which downregulated NFATc1, c-Fos, TNF-α, IL-6 and ROS in Mφs through the RANKL downstream pathway to inhibit osteoclastogenesis. Lee et al. (2013) Studies have shown that acteoside suppresses the differentiation of macrophage-like cells induced by IL-32 and the inflammatory response through the JAK/STAT pathway. Nam et al. (2015); Qiao et al. (2019) The immune regulation mechanism may selectively enhance the production of IFN-γ by T cells and promote the production of IL-10 derived from B cells by regulating the TLR4/PI3K pathway. Wu et al. (2022b); Song et al. (2016b); (Figure 2); (Table 4).
TABLE 4. Immunoregulation mechanisms by which nourishing kidney-yin of single preparations and their active ingredients inhibit osteoclastogenesis.
5 Conclusion and prospects
Remarkable progress has been made in understanding the regulatory mechanisms of kidney-tonifying herbs on OCs based on the immune system. Through the repeated in vivo and in vitro experiments collected in this study, the involved immune cells and signalling pathways of the anti-OC effect in tonifying kidney-yang herbs are understood to be more extensive. By regulating Th1, Th2, Th17, Treg, Mφ, and BMSC cells and secreted cytokines and based on the RANK/RANKL signalling pathway, tonifying kidney-yang and nourishing kidney-yin herbs regulate the surface precursor receptors, downstream signalling pathways, transcription factors and OC genes to inhibit OC generation and differentiation. Based on the above, the difference between kidney-yang and kidney-yin herbs is that kidney-yang herbs regulate MMP-2 and MMP-13 genes and have more advantages in treating osteolytic disease and posttumor bone metastases; the kidney-tonifying herbs regulate the OC-STAMP gene and have more advantages in the treatment of estrogen-related diseases, but the differences in the regulation of immune cells are not obvious. Screening for kidney-tonifying herbs with OC biological effect-based immune responses should be further carried out due to the complexity of the active components of botanical drugs. The compound prescription of TCM should receive more consideration as the basic form of clinical application. However, the selected original articles have certain limitations, such as lacking research on the drug dose range, lacking co-culture system for cell models, which lack innovation and guidance for further research. Importantly, the difference between tonifying kidney-yang herbs and nourishing kidney-yin herbs needs to be demonstrated from the perspective of epigenetics and using cell co-culture technology, which may be evidence for the classification basis of botanical drugs and provide additional evidence for selecting more targeted botanical drugs in the clinic.
Author contributions
CX and YX designed the framework of the article. YJ wrote the manuscript. XW, QW, QG, XC, and TD took part in discussions related to the manuscript. MZ and LZ performed literature review. The manuscript was revised and approved by CX and YX. All authors made contributions to the article and approved the submitted version.
Funding
National High Level Hospital Clinical Research Funding (Grant number 2022-NHLHCRF-LX-02-0105), The National Natural Science Foundation of China (Grant number 81873223), and Beijing Chinese Medicine Science and Technology Development Fund Project (Youth Planning Project): QN-2020-32 financially supported this research.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Andreev, D., Kachler, K., Schett, G., and Bozec, A. (2022). Rheumatoid arthritis and osteoimmunology: The adverse impact of a deregulated immune system on bone metabolism. Bone 162, 116468. doi:10.1016/j.bone.2022.116468
Ang, E. S., Yang, X., Chen, H., Liu, Q., Zheng, M. H., and Xu, J. (2011). Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-κB and ERK activation. FEBS Lett. 585 (17), 2755–2762. doi:10.1016/j.febslet.2011.07.046
Axmann, R., Herman, S., Zaiss, M., Franz, S., Polzer, K., Zwerina, J., et al. (2008). CTLA-4 directly inhibits osteoclast formation. Ann. Rheum. Dis. 67 (11), 1603–1609. doi:10.1136/ard.2007.080713
Boyce, B. F. (2013). Advances in the regulation of osteoclasts and osteoclast functions. J. Dent. Res. 92 (10), 860–867. doi:10.1177/0022034513500306
Boyle, W. J., Simonet, W. S., and Lacey, D. L. (2003). Osteoclast differentiation and activation. Nature 423 (6937), 337–342. doi:10.1038/nature01658
Cao, J. F. (2021). Study on the mechanism of Yishen Juanbi pill inhibiting osteoclast differentiation and function based on EphrinB2 signal pathway. M.D. thesis (Beijing, China: China Academy of Chinese Medical Sciences). in Chinese. doi:10.27658/d.cnki.gzzyy.2021.000201
Chai, L., Zhou, K., Wang, S., Zhang, H., Fan, N., Li, J., et al. (2018). Psoralen and Bakuchiol ameliorate M-CSF plus RANKL-induced osteoclast differentiation and bone resorption via inhibition of AKT and AP-1 pathways in vitro. Cell Physiol. biochem. 48 (5), 2123–2133. doi:10.1159/000492554
Chen, H., Fang, C., Zhi, X., Song, S., Gu, Y., Chen, X., et al. (2020a). Neobavaisoflavone inhibits osteoclastogenesis through blocking RANKL signalling-mediated TRAF6 and c-Src recruitment and NF-κB, MAPK and Akt pathways. J. Cell Mol. Med. 24 (16), 9067–9084. doi:10.1111/jcmm.15543
Chen, J., Xie, L. H., Li, S. Q., Xu, H. J., Chen, S. N., and Ge, J. R. (2017). Relationship between JAK/STAT pathway and immunomodulatory effects of Liuwei Dihuang Pills on postmenopausal osteoporosis patients with syndrome of deficiency of kidney yin. (in Chinese). China J. Traditional Chin. Med. Pharm. 32 (04), 1747–1750.
Chen, Z., Liu, J., Kong, X., and Li, H. (2020b). Characterization and immunological activities of Polysaccharides from Polygonatum sibiricum. Biol. Pharm. Bull. 43 (6), 959–967. doi:10.1248/bpb.b19-00978
Cheng, C. F., Chien-Fu Lin, J., Tsai, F. J., Chen, C. J., Chiou, J. S., Chou, C. H., et al. (2019). Protective effects and network analysis of natural compounds obtained from Radix dipsaci, Eucommiae cortex, and Rhizoma drynariae against RANKL-induced osteoclastogenesis in vitro. J. Ethnopharmacol. 244, 112074. doi:10.1016/j.jep.2019.112074
Chi, L., Gao, W., Shu, X., and Lu, X. (2014). A natural flavonoid glucoside, icariin, regulates Th17 and alleviates rheumatoid arthritis in a murine model. Mediat. Inflamm. 2014, 392062. doi:10.1155/2014/392062
Choi, Y., and Kim, J. J. (2003). B cells activated in the presence of Th1 cytokines inhibit osteoclastogenesis. Exp. Mol. Med. 35 (5), 385–392. doi:10.1038/emm.2003.51
Del Fattore, A., and Teti, A. (2012). The tight relationship between osteoclasts and the immune system. Inflamm. Allergy Drug Targets 11 (3), 181–187. doi:10.2174/187152812800392733
Deng, X., Liang, L. N., Zhu, D., Zheng, L. P., Yu, J. H., Meng, X. L., et al. (2018). Wedelolactone inhibits osteoclastogenesis but enhances osteoblastogenesis through altering different semaphorins production. Int. Immunopharmacol. 60, 41–49. doi:10.1016/j.intimp.2018.04.037
Deng, Z., Zhang, Q., Zhao, Z., Li, Y., Chen, X., Lin, Z., et al. (2021). Crosstalk between immune cells and bone cells or chondrocytes. Int. Immunopharmacol. 101, 108179. doi:10.1016/j.intimp.2021.108179
Di, Y., Zhang, M., Chen, Y., Sun, R., Shen, M., Tian, F., et al. (2022). Catalpol inhibits Tregs-to-Th17 cell transdifferentiation by up-regulating Let-7g-5p to reduce STAT3 protein levels. Yonsei Med. J. 63 (1), 56–65. doi:10.3349/ymj.2022.63.1.56
Dou, C., Ding, N., Zhao, C., Hou, T., Kang, F., Cao, Z., et al. (2018). Estrogen deficiency-mediated M2 macrophage osteoclastogenesis contributes to M1/M2 ratio alteration in ovariectomized osteoporotic mice. J. Bone Min. Res. 33 (5), 899–908. doi:10.1002/jbmr.3364
Du, L., Nong, M. N., Zhao, J. M., Peng, X. M., Zong, S. H., and Zeng, G. F. (2016). Polygonatum sibiricum polysaccharide inhibits osteoporosis by promoting osteoblast formation and blocking osteoclastogenesis through Wnt/β-catenin signalling pathway. Sci. Rep. 6, 32261. doi:10.1038/srep32261
Fan, D., Xia, Y., Lu, C., Ye, Q., Xi, X., Wang, Q., et al. (2020). Regulatory role of the RNA N(6)-methyladenosine modification in immunoregulatory cells and immune-related bone homeostasis associated with rheumatoid arthritis. Front. Cell Dev. Biol. 8, 627893. doi:10.3389/fcell.2020.627893
Feng, S., Madsen, S. H., Viller, N. N., Neutzsky-Wulff, A. V., Geisler, C., Karlsson, L., et al. (2015). Interleukin-15-activated natural killer cells kill autologous osteoclasts via LFA-1, DNAM-1 and TRAIL, and inhibit osteoclast-mediated bone erosion in vitro. Immunology 145 (3), 367–379. doi:10.1111/imm.12449
Gao, Y., Grassi, F., Ryan, M. R., Terauchi, M., Page, K., Yang, X., et al. (2007). IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J. Clin. Invest. 117 (1), 122–132. doi:10.1172/jci30074
Gohda, J., Akiyama, T., Koga, T., Takayanagi, H., Tanaka, S., and Inoue, J. (2005). RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J. 24 (4), 790–799. doi:10.1038/sj.emboj.7600564
Gonzalez, M. Z., Volk-Draper, L., Bhattarai, N., Wilber, A., and Ran, S. (2022). Th2 cytokines IL-4, IL-13, and IL-10 promote differentiation of pro-lymphatic progenitors derived from bone marrow myeloid precursors. Stem Cells Dev. 31 (11-12), 322–333. doi:10.1089/scd.2022.0004
Grčević, D., Sanjay, A., and Lorenzo, J. (2021). Interactions of B-lymphocytes and bone cells in health and disease. Bone 168, 116296. doi:10.1016/j.bone.2021.116296
Guo, M. H., Xu, H. H., Li, X. Y., Wang, G., Huang, J., Lv, S., et al. (2018). Effects of Yishen Jubi Pill on osteoclast differentiation and function in osteoclast-regulatory T cell co culture system. (in Chinese). J. Basic Chin. Med. 24 (05), 596–599.
Han, L. (2021). Experimental study on improving postmenopausal osteoporosis with Bu Shen Tong Luo formula based on Chemerin. M.D. thesis (Nanjing, China: Nanjing University Of Chinese Medicine). in Chinese. doi:10.27253/d.cnki.gnjzu.2021.000218
Han, S. Y., and Kim, Y. K. (2021). Yukmijihwang-Tang suppresses receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclast differentiation and prevents ovariectomy (OVX)-mediated bone loss. Molecules 26 (24), 7579. doi:10.3390/molecules26247579
He, Y. Q., Zhang, Q., Shen, Y., Han, T., Zhang, Q. L., Zhang, J. H., et al. (2018). Rubiadin-1-methyl ether from Morinda officinalis How. inhibits osteoclastogenesis through blocking RANKL-induced NF-κB pathway. Biochem. Biophys. Res. Commun. 506 (4), 927–931. doi:10.1016/j.bbrc.2018.10.100
Hejazi, I. I., Khanam, R., Mehdi, S. H., Bhat, A. R., Rizvi, M. M. A., Thakur, S. C., et al. (2018). Antioxidative and anti-proliferative potential of Curculigo orchioides Gaertn in oxidative stress induced cytotoxicity: In vitro, ex vivo and in silico studies. Food Chem. Toxicol. 115, 244–259. doi:10.1016/j.fct.2018.03.013
Hong, G., Zhou, L., Shi, X., He, W., Wang, H., Wei, Q., et al. (2017). Bajijiasu abrogates osteoclast differentiation via the suppression of RANKL signaling pathways through NF-κB and NFAT. Int. J. Mol. Sci. 18 (1), 203. doi:10.3390/ijms18010203
Hsieh, C. J., Kuo, P. L., Hou, M. F., Hung, J. Y., Chang, F. R., Hsu, Y. C., et al. (2015). Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling. Int. J. Oncol. 46 (2), 555–562. doi:10.3892/ijo.2014.2769
Hsieh, T. P., Sheu, S. Y., Sun, J. S., and Chen, M. H. (2011). Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-κB regulated HIF-1α and PGE(2) synthesis. Phytomedicine 18 (2-3), 176–185. doi:10.1016/j.phymed.2010.04.003
Ilesanmi-Oyelere, B. L., Schollum, L., Kuhn-Sherlock, B., McConnell, M., Mros, S., Coad, J., et al. (2019). Inflammatory markers and bone health in postmenopausal women: A cross-sectional overview. Immun. Ageing 16, 15. doi:10.1186/s12979-019-0155-x
Jeong, J. C., Lee, B. T., Yoon, C. H., Kim, H. M., and Kim, C. H. (2005). Effects of Drynariae rhizoma on the proliferation of human bone cells and the immunomodulatory activity. Pharmacol. Res. 51 (2), 125–136. doi:10.1016/j.phrs.2004.06.005
Ji, R., Wu, D., and Liu, Q. (2022). Icariin inhibits RANKL-induced osteoclastogenesis in RAW264.7 cells via inhibition of reactive oxygen species production by reducing the expression of NOX1 and NOX4. Biochem. Biophys. Res. Commun. 600, 6–13. doi:10.1016/j.bbrc.2022.02.023
Ju, D., Liu, M., Zhao, H., and Wang, J. (2014). Mechanisms of "kidney governing bones" theory in traditional Chinese medicine. Front. Med. 8 (3), 389–393. doi:10.1007/s11684-014-0362-y
Kelchtermans, H., Geboes, L., Mitera, T., Huskens, D., Leclercq, G., and Matthys, P. (2009). Activated CD4+CD25+ regulatory T cells inhibit osteoclastogenesis and collagen-induced arthritis. Ann. Rheum. Dis. 68 (5), 744–750. doi:10.1136/ard.2007.086066
Kim, B., Lee, K. Y., and Park, B. (2018). Icariin abrogates osteoclast formation through the regulation of the RANKL-mediated TRAF6/NF-κB/ERK signaling pathway in Raw264.7 cells. Phytomedicine 51, 181–190. doi:10.1016/j.phymed.2018.06.020
Kim, Y. G., Lee, C. K., Nah, S. S., Mun, S. H., Yoo, B., and Moon, H. B. (2007). Human CD4+CD25+ regulatory T cells inhibit the differentiation of osteoclasts from peripheral blood mononuclear cells. Biochem. Biophys. Res. Commun. 357 (4), 1046–1052. doi:10.1016/j.bbrc.2007.04.042
Kodama, J., and Kaito, T. (2020). Osteoclast multinucleation: Review of current literature. Int. J. Mol. Sci. 21 (16), 5685. doi:10.3390/ijms21165685
Koga, T., Inui, M., Inoue, K., Kim, S., Suematsu, A., Kobayashi, E., et al. (2004). Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428 (6984), 758–763. doi:10.1038/nature02444
Kong, Y. Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., et al. (1999). Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 (6759), 304–309. doi:10.1038/46303
Lai, N., Zhang, Z., Wang, B., Miao, X., Guo, Y., Yao, C., et al. (2015). Regulatory effect of traditional Chinese medicinal formula Zuo-Gui-Wan on the Th17/Treg paradigm in mice with bone loss induced by estrogen deficiency. J. Ethnopharmacol. 166, 228–239. doi:10.1016/j.jep.2015.03.011
Lee, A., Yang, H., Kim, T., Ha, H., and Hwang, Y. H. (2021). Identification and pharmacokinetics of bioavailable anti-resorptive phytochemicals after oral administration of Psoralea corylifolia L. Biomed. Pharmacother. 144, 112300. doi:10.1016/j.biopha.2021.112300
Lee, S. Y., Lee, K. S., Yi, S. H., Kook, S. H., and Lee, J. C. (2013). Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production. PLoS One 8 (12), e80873. doi:10.1371/journal.pone.0080873
Levescot, A., Chang, M. H., Schnell, J., Nelson-Maney, N., Yan, J., Martínez-Bonet, M., et al. (2021). IL-1β-driven osteoclastogenic Tregs accelerate bone erosion in arthritis. J. Clin. Invest. 131 (18), e141008. doi:10.1172/jci141008
Li, B., Wu, P., Fu, W., Xiong, Y., Zhang, L., Gao, Y., et al. (2019). The role and mechanism of miRNA-1224 in the Polygonatum sibiricum polysaccharide regulation of bone marrow-derived macrophages to osteoclast differentiation. Rejuvenation Res. 22 (5), 420–430. doi:10.1089/rej.2018.2126
Li, F. B., Sun, X. L., Ma, J. X., Zhang, Y., Zhao, B., Li, Y. J., et al. (2015). Effect of naringin on osteoclast differentiation. Zhongguo Zhong Yao Za Zhi 40 (2), 308–312.
Li, F., Sun, X., Ma, J., Ma, X., Zhao, B., Zhang, Y., et al. (2014). Naringin prevents ovariectomy-induced osteoporosis and promotes osteoclasts apoptosis through the mitochondria-mediated apoptosis pathway. Biochem. Biophys. Res. Commun. 452 (3), 629–635. doi:10.1016/j.bbrc.2014.08.117
Li, J. F., Wu, D., Xiao, Y. K., Hu, C., Wu, Y. N., Li, Q., et al. (2017). Effect of Bushen Quhan Zhiwang decoction on serum IL-17, OPG and RANKL levels in rats with collagen induced arthritis. (in Chinese). Acta Chin. Med. 32 (12), 2415–2419. doi:10.16368/j.issn.1674-8999.2017.12.628
Li, J. P., Xie, B. P., Zhang, W. J., Shi, L. Y., Li, W. J., Zeng, Y., et al. (2018). Psoralen inhibits RAW264.7 differentiation into osteoclasts and bone resorption by regulating CD4+T cell differentiation. Zhongguo Zhong Yao Za Zhi 43 (6), 1228–1234. doi:10.19540/j.cnki.cjcmm.20180104.017
Li, X., Xu, H., Huang, J., Luo, D., Lv, S., Lu, X., et al. (2021). Dysfunctions, molecular mechanisms, and therapeutic strategies of regulatory T cells in rheumatoid arthritis. Front. Pharmacol. 12, 716081. doi:10.3389/fphar.2021.716081
Li, Y. Y. (2021). Study on the anti osteoporosis activity of Yishen Bugu liquid based on the regulation of osteoblast differentiation and osteoclast differentiation. M.D. thesis (Jilin, China: Jilin University). in Chinese. doi:10.27162/d.cnki.gjlin.2021.005085
Li, Z. W., Ren, R. Y., Li, M. W., Liu, Q. K., Yu, X. J., Jiang, Y. Q., et al. (2022). Icariin inhibits osteoclast formation by promoting the expression of negative requlator Gα13. (in Chinese). Orthopaedics 13 (02), 155–159.
Liao, C., Zhang, C., Jin, L., and Yang, Y. (2020). IL-17 alters the mesenchymal stem cell niche towards osteogenesis in cooperation with osteocytes. J. Cell Physiol. 235 (5), 4466–4480. doi:10.1002/jcp.29323
Liu, C., Ma, R., Wang, L., Zhu, R., Liu, H., Guo, Y., et al. (2017). Rehmanniae Radix in osteoporosis: A review of traditional Chinese medicinal uses, phytochemistry, pharmacokinetics and pharmacology. J. Ethnopharmacol. 198, 351–362. doi:10.1016/j.jep.2017.01.021
Liu, F., Tan, F., Tong, W., Fan, Q., Ye, S., Lu, S., et al. (2018). Effect of Zuoguiwan on osteoporosis in ovariectomized rats through RANKL/OPG pathway mediated by β2AR. Biomed. Pharmacother. 103, 1052–1060. doi:10.1016/j.biopha.2018.04.102
Liu, H., Wang, G., Wang, J., Wang, T., Tian, J., Wang, L., et al. (2021a). Bushentongluo recipe (BSTL) attenuates bone destruction by inhibiting NF-κB/RANK/RANKL pathway in collagen-induced arthritis (CIA) rats. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 37 (3), 205–211.
Liu, M., Liu, S., Zhang, Q., Fang, Y., Yu, Y., Zhu, L., et al. (2021b). Curculigoside attenuates oxidative stress and osteoclastogenesis via modulating Nrf2/NF-κB signaling pathway in RAW264.7 cells. J. Ethnopharmacol. 275, 114129. doi:10.1016/j.jep.2021.114129
Liu, Y. Q., Han, X. F., Bo, J. X., and Ma, H. P. (2016a). Wedelolactone enhances osteoblastogenesis but inhibits osteoclastogenesis through Sema3A/NRP1/PlexinA1 pathway. Front. Pharmacol. 7, 375. doi:10.3389/fphar.2016.00375
Liu, Y. Q., Hong, Z. L., Zhan, L. B., Chu, H. Y., Zhang, X. Z., and Li, G. H. (2016b). Wedelolactone enhances osteoblastogenesis by regulating Wnt/β-catenin signaling pathway but suppresses osteoclastogenesis by NF-κB/c-fos/NFATc1 pathway. Sci. Rep. 6, 32260. doi:10.1038/srep32260
Liu, Z. W. (2021). Study on the mechanism of Aikeqing granule inhibiting osteoclast differentiation and improving bone loss in ovariectomized rats. PhD. thesis (Guangzhou, China: Guangzhou University of Chinese Medicine). in Chinese. doi:10.27044/d.cnki.ggzzu.2021.000059
Luo, C. Y., Wang, L., Sun, C., and Li, D. J. (2011). Estrogen enhances the functions of CD4(+)CD25(+)Foxp3(+) regulatory T cells that suppress osteoclast differentiation and bone resorption in vitro. Cell Mol. Immunol. 8 (1), 50–58. doi:10.1038/cmi.2010.54
Ma, R. (2021). Study on the mechanism of Zhiwang decoction on anti inflammation and bone destruction in collagen induced arthritis rats. M.D. thesis (Beijing, China: Beijing University of Chinese Medicine). in Chinese. doi:10.26973/d.cnki.gbjzu.2021.000908
Ma, Y., Wang, L., Zheng, S., Xu, J., Pan, Y., Tu, P., et al. (2019). Osthole inhibits osteoclasts formation and bone resorption by regulating NF-κB signaling and NFATc1 activations stimulated by RANKL. J. Cell Biochem. 120 (9), 16052–16061. doi:10.1002/jcb.28886
Madel, M. B., Ibáñez, L., Wakkach, A., de Vries, T. J., Teti, A., Apparailly, F., et al. (2019). Immune function and diversity of osteoclasts in normal and pathological conditions. Front. Immunol. 10, 1408. doi:10.3389/fimmu.2019.01408
Manabe, N., Kawaguchi, H., Chikuda, H., Miyaura, C., Inada, M., Nagai, R., et al. (2001). Connection between B lymphocyte and osteoclast differentiation pathways. J. Immunol. 167 (5), 2625–2631. doi:10.4049/jimmunol.167.5.2625
Mansour, A., Anginot, A., Mancini, S. J., Schiff, C., Carle, G. F., Wakkach, A., et al. (2011). Osteoclast activity modulates B-cell development in the bone marrow. Cell Res. 21 (7), 1102–1115. doi:10.1038/cr.2011.21
Meednu, N., Zhang, H., Owen, T., Sun, W., Wang, V., Cistrone, C., et al. (2016). Production of RANKL by memory B cells: A link between B cells and bone erosion in rheumatoid arthritis. Arthritis Rheumatol. 68 (4), 805–816. doi:10.1002/art.39489
Meng, J., Zhang, W., Wang, C., Zhang, W., Zhou, C., Jiang, G., et al. (2020). Catalpol suppresses osteoclastogenesis and attenuates osteoclast-derived bone resorption by modulating PTEN activity. Biochem. Pharmacol. 171, 113715. doi:10.1016/j.bcp.2019.113715
Murali, V. P., and Kuttan, G. (2015). Enhancement of cancer chemotherapeutic efficacy of cyclophosphamide by Curculigo orchioides Gaertn and its ameliorative effects on cyclophosphamide-induced oxidative stress. Integr. Cancer Ther. 14 (2), 172–183. doi:10.1177/1534735414564424
Nam, S. Y., Kim, H. M., and Jeong, H. J. (2015). Attenuation of IL-32-induced caspase-1 and nuclear factor-κB activations by acteoside. Int. Immunopharmacol. 29 (2), 574–582. doi:10.1016/j.intimp.2015.09.026
Okamoto, K., Nakashima, T., Shinohara, M., Negishi-Koga, T., Komatsu, N., Terashima, A., et al. (2017). Osteoimmunology: The conceptual framework unifying the immune and skeletal systems. Physiol. Rev. 97 (4), 1295–1349. doi:10.1152/physrev.00036.2016
Pai, F. T., Lu, C. Y., Lin, C. H., Wang, J., Huang, M. C., Liu, C. T., et al. (2021). Psoralea corylifolia L. ameliorates collagen-induced arthritis by reducing proinflammatory cytokines and upregulating myeloid-derived suppressor cells. Life (Basel) 11 (6), 587. doi:10.3390/life11060587
Palmqvist, P., Lundberg, P., Persson, E., Johansson, A., Lundgren, I., Lie, A., et al. (2006). Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J. Biol. Chem. 281 (5), 2414–2429. doi:10.1074/jbc.M510160200
Park, J. H., Lee, N. K., and Lee, S. Y. (2017). Current understanding of RANK signaling in osteoclast differentiation and maturation. Mol. Cells 40 (10), 706–713. doi:10.14348/molcells.2017.0225
Peng, M., and Zhong, B. N. (2020). Study on the mechanism of OPG/RANK/RANK signaling pathway in Morinda officinalis polysaccharide in the treatment of postmenopausal osteoporosis. (in Chinese). Electron. J. Pract. Gynecol. Endocrinol. 7 (34), 61–62. doi:10.16484/j.cnki.issn2095-8803.2020.34.044
Perera, P. K., Peng, C., Xue, L., Li, Y., and Han, C. (2011). Ex vivo and in vivo effect of Chinese herbal pill Yi Shen Juan Bi (YJB) on experimental arthritis. J. Ethnopharmacol. 134 (1), 171–175. doi:10.1016/j.jep.2010.11.065
Poubelle, P. E., Chakravarti, A., Fernandes, M. J., Doiron, K., and Marceau, A. A. (2007). Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils. Arthritis Res. Ther. 9 (2), R25. doi:10.1186/ar2137
Qiao, Z., Tang, J., Wu, W., Tang, J., and Liu, M. (2019). Acteoside inhibits inflammatory response via JAK/STAT signaling pathway in osteoarthritic rats. BMC Complement. Altern. Med. 19 (1), 264. doi:10.1186/s12906-019-2673-7
Qin, X. Y., Niu, Z. C., Han, X. L., Yang, Y., Wei, Q., Gao, X. X., et al. (2021). Anti-perimenopausal osteoporosis effects of Erzhi formula via regulation of bone resorption through osteoclast differentiation: A network pharmacology-integrated experimental study. J. Ethnopharmacol. 270, 113815. doi:10.1016/j.jep.2021.113815
Qiu, G., Bao, X., Li, Y., Liu, J., Yao, S. B., Chen, L., et al. (2008). Effect of ethanol extract of Eucommia ulmoides leaves on immune function in mice Chinese). Pharmacol. Clin. Chin. Mater. Med. (04), 41–43.
Qiu, X., Gui, Y., Zhang, N., Xu, Y., Li, D., and Wang, L. (2016a). Effects of Bu-Shen-Ning-Xin decoction on immune cells of the spleen and bone marrow in ovariectomized mice. Biosci. Trends 10 (5), 400–409. doi:10.5582/bst.2016.01012
Qiu, Z. C., Dong, X. L., Dai, Y., Xiao, G. K., Wang, X. L., Wong, K. C., et al. (2016b). Discovery of a new class of Cathepsin K inhibitors in Rhizoma Drynariae as potential candidates for the treatment of osteoporosis. Int. J. Mol. Sci. 17 (12), 2116. doi:10.3390/ijms17122116
Rivollier, A., Mazzorana, M., Tebib, J., Piperno, M., Aitsiselmi, T., Rabourdin-Combe, C., et al. (2004). Immature dendritic cell transdifferentiation into osteoclasts: A novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 104 (13), 4029–4037. doi:10.1182/blood-2004-01-0041
Roggia, C., Gao, Y., Cenci, S., Weitzmann, M. N., Toraldo, G., Isaia, G., et al. (2001). Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. U. S. A. 98 (24), 13960–13965. doi:10.1073/pnas.251534698
Sato, K., Suematsu, A., Okamoto, K., Yamaguchi, A., Morishita, Y., Kadono, Y., et al. (2006). Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203 (12), 2673–2682. doi:10.1084/jem.20061775
Saxena, Y., Routh, S., and Mukhopadhaya, A. (2021). Immunoporosis: Role of innate immune cells in osteoporosis. Front. Immunol. 12, 687037. doi:10.3389/fimmu.2021.687037
Shao, H., Shen, J., Wang, M., Cui, J., Wang, Y., Zhu, S., et al. (2015). Icariin protects against titanium particle-induced osteolysis and inflammatory response in a mouse calvarial model. Biomaterials 60, 92–99. doi:10.1016/j.biomaterials.2015.04.048
Shashkova, E. V., Trivedi, J., Cline-Smith, A. B., Ferris, C., Buchwald, Z. S., Gibbs, J., et al. (2016). Osteoclast-primed Foxp3+ CD8 T cells induce T-bet, eomesodermin, and IFN-γ to regulate bone resorption. J. Immunol. 197 (3), 726–735. doi:10.4049/jimmunol.1600253
Shim, K. S., Ma, C. J., Kim, D. S., and Ma, J. Y. (2011). Yukmijihwang-tang inhibits receptor activator for nuclear factor-κB ligand-induced osteoclast differentiation. J. Med. Food 14 (11), 1439–1447. doi:10.1089/jmf.2010.1502
Söderström, K., Stein, E., Colmenero, P., Purath, U., Müller-Ladner, U., de Matos, C. T., et al. (2010). Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc. Natl. Acad. Sci. U. S. A. 107 (29), 13028–13033. doi:10.1073/pnas.1000546107
Søe, K., Delaisse, J. M., and Borggaard, X. G. (2021). Osteoclast formation at the bone marrow/bone surface interface: Importance of structural elements, matrix, and intercellular communication. Semin. Cell Dev. Biol. 112, 8–15. doi:10.1016/j.semcdb.2020.05.016
Song, S. H., Zhai, Y. K., Li, C. Q., Yu, Q., Lu, Y., Zhang, Y., et al. (2016a). Effects of total flavonoids from Drynariae Rhizoma prevent bone loss in vivo and in vitro. Bone Rep. 5, 262–273. doi:10.1016/j.bonr.2016.09.001
Song, X., He, J., Xu, H., Hu, X. P., Wu, X. L., Wu, H. Q., et al. (2016b). The antiviral effects of acteoside and the underlying IFN-γ-inducing action. Food Funct. 7 (7), 3017–3030. doi:10.1039/c6fo00335d
Sprangers, S., de Vries, T. J., and Everts, V. (2016). Monocyte heterogeneity: Consequences for monocyte-derived immune cells. J. Immunol. Res. 2016, 1475435. doi:10.1155/2016/1475435
Su, X., Chen, W. W., An, G. W., Yang, X. M., Tang, H. Y., Xia, J., et al. (2010). Study on the regulation of Bu Shen Tong Luo formula on immune function in rats with collagen induced arthritis, 2010 academic meeting of rheumatology branch of Chinese society of traditional Chinese medicine. Xian, China, 114–117. in Chinese.
Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., et al. (2002). Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3 (6), 889–901. doi:10.1016/s1534-5807(02)00369-6
Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., et al. (2000). T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408 (6812), 600–605. doi:10.1038/35046102
Tan, S., Xu, J., Lai, A., Cui, R., Bai, R., Li, S., et al. (2019). Curculigoside exerts significant anti-arthritic effects in vivo and in vitro via regulation of the JAK/STAT/NF-κB signaling pathway. Mol. Med. Rep. 19 (3), 2057–2064. doi:10.3892/mmr.2019.9854
Tang, M., Lu, L., and Yu, X. (2020). Interleukin-17A interweaves the skeletal and immune systems. Front. Immunol. 11, 625034. doi:10.3389/fimmu.2020.625034
Teitelbaum, S. L. (2000). Bone resorption by osteoclasts. Science 289 (5484), 1504–1508. doi:10.1126/science.289.5484.1504
Tian, T., Fu, Q., Zhu, J. K., and Yin, H. (2020). Observation on the effect of Erzhiwan on zebrafish osteoporosis model and study on autophagy mechanism of osteoclast. (in Chinese). J. Nanjing Univ. Traditional Chin. Med. 36 (03), 352–357. doi:10.14148/j.issn.1672-0482.2020.0352
Wang, G. (2017). Effects of Yishen Juanbi pill on bone metabolism and immune regulation in rats with collagen induced arthritis. M.D. thesis (Beijing, China: Beijing University of Chinese Medicine). in Chinese.
Wang, H., Jiang, Q., and Feng, X. (2017). Effect of Icariin on apoptosis and expression of Fas, Fas ligand, B cell lymphoma, and Bcl-2-associated X protein in CD4+ T lymphocytes from patients with ankylosing spondylitis. J. Tradit. Chin. Med. 37 (2), 207–213. doi:10.1016/s0254-6272(17)30046-8
Wang, J., Shan, A., Liu, T., Zhang, C., and Zhang, Z. (2012). In vitro immunomodulatory effects of an oleanolic acid-enriched extract of Ligustrum lucidum fruit (Ligustrum lucidum supercritical CO2 extract) on piglet immunocytes. Int. Immunopharmacol. 14 (4), 758–763. doi:10.1016/j.intimp.2012.10.006
Wang, L., Qiu, X. M., Gui, Y. Y., Xu, Y. P., Gober, H. J., and Li, D. J. (2015). Bu-shen-ning-xin decoction: Inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α. Drug Des. devel. Ther. 9, 3755–3766. doi:10.2147/dddt.S88512
Wang, T., Fan, L., Feng, S., Ding, X., An, X., Chen, J., et al. (2022a). Network pharmacology of iridoid glycosides from Eucommia ulmoides Oliver against osteoporosis. Sci. Rep. 12 (1), 7430. doi:10.1038/s41598-022-10769-w
Wang, Y., Feng, Y., Li, M., Yang, M., Shi, G., Xuan, Z., et al. (2022b). Traditional Chinese medicine in the treatment of chronic kidney diseases: Theories, applications, and mechanisms. Front. Pharmacol. 13, 917975. doi:10.3389/fphar.2022.917975
Wang, Y., Kwak, M., Lee, P. C., and Jin, J. O. (2018a). Rehmannia glutinosa polysaccharide promoted activation of human dendritic cells. Int. J. Biol. Macromol. 116, 232–238. doi:10.1016/j.ijbiomac.2018.04.144
Wang, Z., Wang, D., Yang, D., Zhen, W., Zhang, J., and Peng, S. (2018b). The effect of Icariin on bone metabolism and its potential clinical application. Osteoporos. Int. 29 (3), 535–544. doi:10.1007/s00198-017-4255-1
Weaver, C. T., Harrington, L. E., Mangan, P. R., Gavrieli, M., and Murphy, K. M. (2006). Th17: An effector CD4 T cell lineage with regulatory T cell ties. Immunity 24 (6), 677–688. doi:10.1016/j.immuni.2006.06.002
Wei, X. F., Wang, J., Ren, X. H., Li, X. W., Liu, B. N., and Shi, J. (2019). Effect of Morinda officinalis and its processed products on immune function of immunosuppressed mice. (in Chinese). J. Chin. Med. Mater. 42 (03), 545–548. doi:10.13863/j.issn1001-4454.2019.03.013
Wu, C., Sun, Z., Ye, Y., Han, X., Song, X., and Liu, S. (2013). Psoralen inhibits bone metastasis of breast cancer in mice. Fitoterapia 91, 205–210. doi:10.1016/j.fitote.2013.09.005
Wu, D., Cline-Smith, A., Shashkova, E., Perla, A., Katyal, A., and Aurora, R. (2021). T-cell mediated inflammation in postmenopausal osteoporosis. Front. Immunol. 12, 687551. doi:10.3389/fimmu.2021.687551
Wu, D., Li, J. F., Xiao, Y. K., Hu, C., Wu, Y. N., Li, Q., et al. (2018). Effects of Bushen Quhan Zhiqian decoction on serum IL-1, IL-2 and TNF-α in rheumatoid arthritis model rats horizontal influence. (in Chinese). Chin. J. Gerontol. 38 (07), 1725–1727.
Wu, L., Wang, R., Zhou, Y., Zhao, D., Chen, F., Wu, X., et al. (2022a). Natural killer cells infiltration in the joints exacerbates collagen-induced arthritis. Front. Immunol. 13, 860761. doi:10.3389/fimmu.2022.860761
Wu, M., Yu, S., Chen, Y., Meng, W., Chen, H., He, J., et al. (2022b). Acteoside promotes B cell-derived IL-10 production and ameliorates autoimmunity. J. Leukoc. Biol. 112, 875–885. doi:10.1002/jlb.3ma0422-510r
Wu, P., Jiao, F., Huang, H., Liu, D., Tang, W., Liang, J., et al. (2022c). Morinda officinalis polysaccharide enable suppression of osteoclastic differentiation by exosomes derived from rat mesenchymal stem cells. Pharm. Biol. 60 (1), 1303–1316. doi:10.1080/13880209.2022.2093385
Wu, Y., Humphrey, M. B., and Nakamura, M. C. (2008). Osteoclasts - the innate immune cells of the bone. Autoimmunity 41 (3), 183–194. doi:10.1080/08916930701693180
Xia, Y., Fan, D., Li, X., Lu, X., Ye, Q., Xi, X., et al. (2021). Yi Shen Juan Bi pill regulates the bone immune microenvironment via the JAK2/STAT3 signaling pathway in vitro. Front. Pharmacol. 12, 746786. doi:10.3389/fphar.2021.746786
Xu, D., Lyu, Y., Chen, X., Zhu, X., Feng, J., and Xu, Y. (2016a). Fructus Ligustri Lucidi ethanol extract inhibits osteoclastogenesis in RAW264.7 cells via the RANKL signaling pathway. Mol. Med. Rep. 14 (5), 4767–4774. doi:10.3892/mmr.2016.5849
Xu, H., Zhao, H., Lu, C., Qiu, Q., Wang, G., Huang, J., et al. (2016b). Triptolide inhibits osteoclast differentiation and bone resorption in vitro via enhancing the production of IL-10 and TGF-β1 by regulatory T cells. Mediat. Inflamm. 2016, 8048170. doi:10.1155/2016/8048170
Xu, J. S., Deng, N., and Zhang, X. (2020). Effect of Rhizoma Drynariae on osteoclast dlifferentiation is related to the concentration of drugcontaining serum. (in Chinese). Chin. J. Tissue Eng. Res. 24 (29), 4620–4625.
Xu, Q., Chen, G., Liu, X., Dai, M., and Zhang, B. (2019). Icariin inhibits RANKL-induced osteoclastogenesis via modulation of the NF-κB and MAPK signaling pathways. Biochem. Biophys. Res. Commun. 508 (3), 902–906. doi:10.1016/j.bbrc.2018.11.201
Xu, Y., Yan, H., Zhang, X., Zhuo, J., Han, Y., Zhang, H., et al. (2022). Roles of altered macrophages and cytokines: Implications for pathological mechanisms of postmenopausal osteoporosis, rheumatoid arthritis, and alzheimer's disease. Front. Endocrinol. (Lausanne) 13, 876269. doi:10.3389/fendo.2022.876269
Yan, M. Y. (2012). Effects of Bu shen qu han zhi wang decoction on symptoms and bone destruction in CIA rats. M.D. thesis (Beijing, China: Beijing University of Chinese Medicine). in Chinese.
Yang, D., and Wan, Y. (2019). Molecular determinants for the polarization of macrophage and osteoclast. Semin. Immunopathol. 41 (5), 551–563. doi:10.1007/s00281-019-00754-3
Yang, F., Yang, W. L., Li, M. H., Liu, P., Li, W., Yang, Z. J., et al. (2022). Study on the effect of Jiawei Yanghe decoction on osteoclast activity based on NF-B signaling pathway. (in Chinese). J. Jiangxi Univ. Chin. Med. 34 (01), 84–87.
Yao, G., Wang, Y., Liu, Y., Tao, Y., Dai, W. F., Wang, H., et al. (2014). Promotion of effective fractions from Erzhi pills on immune activity of T lymphocyte. (in Chinese). Chin. Tradit. Pat. Med. 36 (03), 441–446.
Yao, Y., Cai, X., Ren, F., Ye, Y., Wang, F., Zheng, C., et al. (2021). The macrophage-osteoclast axis in osteoimmunity and osteo-related diseases. Front. Immunol. 12, 664871. doi:10.3389/fimmu.2021.664871
Ye, Y. X., Lin, L., Zhao, J. X., Chen, S. Q., and Sun, W. W. (2015). Effect of Eucommia ulmoides polysaccharides on immune function in immunosuppressive mice. (in Chinese). J. Chin. Med. Mater. 38 (07), 1496–1498. doi:10.13863/j.issn1001-4454.2015.07.039
Yin, X. P. (2017). Study on mechanism of "Bu Sheng Pei Yuan" method based on intervention of medicina lindia nmulberry root polysaccharide (MOP) on the immune regulation function of adipose mesenchymal stem cells in psoriasis patients. M.D. thesis (Beijing, China: China Academy of Chinese Medical Sciences). in Chinese.
Yu, D. D., Zhao, D. Y., Yang, F., Yang, D. X., and Yang, G. L. (2020). Study on the mechanism of Chinese herbal compound Deerhorn Glue pill in the prevention and treatment of postmenopausal osteoporosis. (in Chinese). Chin. J. Osteoporos. 26 (11), 1668–1673.
Yu, D. D., Zhao, D. Y., and Yao, X. S. (2018). Chinese medicine compound Antler pill promotes osteoclast apoptosis through PI3K/AKT pathway. (in Chinese). Chin. J. Osteoporos. 24 (07), 874–878.
Yu, Y., Chen, M., Yang, S., Shao, B., Chen, L., Dou, L., et al. (2021). Osthole enhances the immunosuppressive effects of bone marrow-derived mesenchymal stem cells by promoting the Fas/FasL system. J. Cell Mol. Med. 25 (10), 4835–4845. doi:10.1111/jcmm.16459
Yuan, H., Xiao, L., Min, W., Yuan, W., Lu, S., and Huang, G. (2018). Bu-Shen-Tong-Luo decoction prevents bone loss via inhibition of bone resorption and enhancement of angiogenesis in ovariectomy-induced osteoporosis of rats. J. Ethnopharmacol. 220, 228–238. doi:10.1016/j.jep.2018.01.007
Zhang, D., Zhang, S., Jiang, K., Li, T., and Yan, C. (2020). Bioassay-guided isolation and evaluation of anti-osteoporotic polysaccharides from Morinda officinalis. J. Ethnopharmacol. 261, 113113. doi:10.1016/j.jep.2020.113113
Zhang, J., Liu, N., Sun, C., Sun, D., and Wang, Y. (2019a). Polysaccharides from Polygonatum sibiricum Delar. ex Redoute induce an immune response in the RAW264.7 cell line via an NF-κB/MAPK pathway. R. S. C. Adv. 9 (31), 17988–17994. doi:10.1039/c9ra03023a
Zhang, J. L., Qiu, X. M., Zhang, N., Tang, W., Gober, H. J., Li, D. J., et al. (2018). Bu-Shen-Ning-Xin decoction suppresses osteoclastogenesis by modulating RANKL/OPG imbalance in the CD4+ T lymphocytes of ovariectomized mice. Int. J. Mol. Med. 42 (1), 299–308. doi:10.3892/ijmm.2018.3645
Zhang, J. W., Li, Y., Xue, H. P., Li, Z. H., Nie, W. Z., and Xu, Z. W. (2019b). Rhizoma drynaria inhibits osteoclasts by regulating OPG/RANKL/RANK of bone marrow mesenchymal stem cells. (in Chinese). Chin. J. Osteoporos. 25 (05), 617–624.
Zhang, L. C. (2019). Effects of Zuogui pill containing serum on osteoclast differentiation and osteoclast related inflammatory factors based on ER pathway. M.D. thesis (Liaoning, China: Liaoning University Of Traditional Chinese Medicine). in Chinese. doi:10.27213/d.cnki.glnzc.2019.000566
Zhang, R., Pan, Y. L., Hu, S. J., Kong, X. H., Juan, W., and Mei, Q. B. (2014). Effects of total lignans from Eucommia ulmoides barks prevent bone loss in vivo and in vitro. J. Ethnopharmacol. 155 (1), 104–112. doi:10.1016/j.jep.2014.04.031
Zhang, S., Feng, P., Mo, G., Li, D., Li, Y., Mo, L., et al. (2017a). Icariin influences adipogenic differentiation of stem cells affected by osteoblast-osteoclast co-culture and clinical research adipogenic. Biomed. Pharmacother. 88, 436–442. doi:10.1016/j.biopha.2017.01.050
Zhang, Y., Jiang, J., Shen, H., Chai, Y., Wei, X., and Xie, Y. (2017b). Total flavonoids from rhizoma drynariae (gusuibu) for treating osteoporotic fractures: Implication in clinical practice. Drug Des. devel. Ther. 11, 1881–1890. doi:10.2147/dddt.S139804
Zhang, Y., Wang, J. Y., Chen, X. Y., Zhang, L., and Yuan, Y. (2021). Effects of ethanol extracts of barks and leaves from Eucommia ulmoides on inflammatory bone destruction in collagen-induced arthritis rats based on NF-κB pathway. (in Chinese). Chin. Traditional Herb. Drugs 52 (06), 1645–1653.
Zhao, D., Wang, Q., Zhao, Y., Zhang, H., Sha, N., Tang, D., et al. (2018a). The naturally derived small compound Osthole inhibits osteoclastogenesis to prevent ovariectomy-induced bone loss in mice. Menopause 25 (12), 1459–1469. doi:10.1097/gme.0000000000001150
Zhao, G., He, G. L., Lu, C. Y., Lao, L. L., Pan, Y. Z., Zhou, M. L., et al. (2016). Immunoregulation effect of rhizoma drynariae flavonoids on immunosuppressive mice. (in Chinese). Nat. Prod. Res. Dev. 28 (03), 438–445. doi:10.16333/j.1001-6880.2016.3.022
Zhao, H., Xu, H., Zuo, Z., Wang, G., Liu, M., Guo, M., et al. (2018b). Yi Shen Juan Bi Pill ameliorates bone loss and destruction induced by arthritis through modulating the balance of cytokines released by different subpopulations of T cells. Front. Pharmacol. 9, 262. doi:10.3389/fphar.2018.00262
Zhao, H., Zhao, N., Zheng, P., Xu, X., Liu, M., Luo, D., et al. (2018c). Prevention and treatment of osteoporosis using Chinese medicinal plants: Special emphasis on mechanisms of immune modulation. J. Immunol. Res. 2018, 6345857. doi:10.1155/2018/6345857
Zhao, Z., Hou, X., Yin, X., Li, Y., Duan, R., Boyce, B. F., et al. (2015). TNF induction of NF-κB RelB enhances RANKL-induced osteoclastogenesis by promoting inflammatory macrophage differentiation but also limits it through suppression of NFATc1 expression. PLoS One 10 (8), e0135728. doi:10.1371/journal.pone.0135728
Zheng, J., Wu, M., Wang, H., Li, S., Wang, X., Li, Y., et al. (2018). Network pharmacology to unveil the biological basis of health-strengthening herbal medicine in cancer treatment. Cancers (Basel) 10 (11), 461. doi:10.3390/cancers10110461
Zhou, P., Zheng, T., and Zhao, B. (2022). Cytokine-mediated immunomodulation of osteoclastogenesis. Bone 164, 116540. doi:10.1016/j.bone.2022.116540
Zhou, Y., Wang, S., Feng, W., Zhang, Z., and Li, H. (2021). Structural characterization and immunomodulatory activities of two polysaccharides from Rehmanniae Radix Praeparata. Int. J. Biol. Macromol. 186, 385–395. doi:10.1016/j.ijbiomac.2021.06.100
Zhou, Z. X., and Tang, D. C. (2016). Traditional Chinese medicine. Beijing, China: China Press of Traditional Chinese Medicine, 379–414.
Zhu, F., Wang, J., Ni, Y., Yin, W., Hou, Q., Zhang, Y., et al. (2021). Curculigoside protects against Titanium Particle-induced osteolysis through the enhancement of osteoblast differentiation and reduction of osteoclast formation. J. Immunol. Res. 2021, 5707242. doi:10.1155/2021/5707242
Keywords: kidney-tonifying Chinese herbs, tonifying kidney-yang herbs, nourishing kidney-yin herbs, osteoclasts, immune cells
Citation: Jiao Y, Wang X, Wang Q, Geng Q, Cao X, Zhang M, Zhao L, Deng T, Xu Y and Xiao C (2023) Mechanisms by which kidney-tonifying Chinese herbs inhibit osteoclastogenesis: Emphasis on immune cells. Front. Pharmacol. 14:1077796. doi: 10.3389/fphar.2023.1077796
Received: 23 October 2022; Accepted: 25 January 2023;
Published: 06 February 2023.
Edited by:
Longhuo Wu, Gannan Medical University, ChinaReviewed by:
Ye Xiao, Xiangya Hospital, Central South University, ChinaDaohua Xu, Guangdong Medical University, China
Copyright © 2023 Jiao, Wang, Wang, Geng, Cao, Zhang, Zhao, Deng, Xu and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yuan Xu, xuyuan2004020@163.com; Cheng Xiao, xc2002812@126.com